The Mississippi State Department of Health said a “mass re-testing” began Wednesday on some cannabis products pulled last month from dispensaries.The MSDH Mississippi Medical Cannabis Program took some products off the shelves Dec. 21 after health officials said discrepancies were found “during an audit of Certificates of Analysis surrounding original test results for pesticides and mycotoxins completed by Rapid Analytics.”In a Thursday news release, MSDH said the re-testing process is expected to take two or three weeks, and cleared batches of products will be released each Friday until complete. The re-testing will begin first with flower/bud because health officials said it serves as the base for many products. Concentrates and infused products will be re-tested next. The Mississippi Medical Cannabis Program is covering the cost for all re-testing of products.“Patient safety is our top priority,” said Laura Goodson, director of the Mississippi Medical Cannabis Program. “We are tasked with making sure all test results meet the regulatory standards and that approved products are available to those in the medical cannabis program.” An investigation into the discrepancies is ongoing. Patients are encouraged to contact dispensaries to see what products are available.
The Mississippi State Department of Health said a “mass re-testing” began Wednesday on some cannabis products pulled last month from dispensaries.
The MSDH Mississippi Medical Cannabis Program took some products off the shelves Dec. 21 after health officials said discrepancies were found “during an audit of Certificates of Analysis surrounding original test results for pesticides and mycotoxins completed by Rapid Analytics.”
Advertisement
In a Thursday news release, MSDH said the re-testing process is expected to take two or three weeks, and cleared batches of products will be released each Friday until complete. The re-testing will begin first with flower/bud because health officials said it serves as the base for many products. Concentrates and infused products will be re-tested next.
The Mississippi Medical Cannabis Program is covering the cost for all re-testing of products.
“Patient safety is our top priority,” said Laura Goodson, director of the Mississippi Medical Cannabis Program. “We are tasked with making sure all test results meet the regulatory standards and that approved products are available to those in the medical cannabis program.”
An investigation into the discrepancies is ongoing.
Patients are encouraged to contact dispensaries to see what products are available.
